Literature DB >> 16248837

Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions.

Eun Ju Jeong1, Xing Liu, Xiaobin Jia, Jun Chen, Ming Hu.   

Abstract

Abstract: Conjugating enzymes are traditionally recognized as one of the major biological barriers to the entry of xenobiotics/drugs into systemic circulation and represent one of the main pathways for their elimination. Similar to drugs that undergo extensive phase I metabolism, drugs that undergo extensive conjugation have poor bioavailability and are more prone to metabolism-based drug interactions. Previously, enterohepatic recycling is used to explain why certain xenobiotics have half-lives that are much longer than expected from intravenous injection studies. In addition, changes in expression levels of metabolic enzymes due to chemical induction or suppression are often recognized as the source of drug interaction or toxicity of pollutants and carcinogens. These traditional approaches, whereas yielding highly valuable information, fail to recognize the fact that many conjugates (especially hydrophilic ones) cannot permeate the cell membrane. In the present review, we will focus on the coupling process that involves both conjugating enzymes and efflux transporters. We will briefly review conjugating enzymes capable of producing highly hydrophilic metabolic products. The other focus of this review is on various transporters capable of moving negatively charged hydrophilic conjugates across the cellular membrane. Evidence will support the hypothesis that efficient coupling of the conjugating enzymes and efflux transporters enables enterohepatic recycling and enteric recycling processes. Termed as a "revolving door" theory, the hypothesis focuses on the role played by efflux transporter capable of modulating the cellular excretion of hydrophilic metabolites. Coupling process in intestine, liver and kidney will be discussed with an emphasis on the intestinal coupling process, since we have just begun to understand it. Biological consequence and new insights into how coupling process can impact bioavailability of xenobiotics, biological functions of drugs and carcinogens, and drug interactions will be discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16248837     DOI: 10.2174/138920005774330657

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  27 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

Review 2.  First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.

Authors:  Baojian Wu; Kaustubh Kulkarni; Sumit Basu; Shuxing Zhang; Ming Hu
Journal:  J Pharm Sci       Date:  2011-04-11       Impact factor: 3.534

3.  Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Regulate the Disposition of Acacetin Glucuronides.

Authors:  Huangyu Jiang; Jia Yu; Haihui Zheng; Jiamei Chen; Jinjun Wu; Xiaoxiao Qi; Ying Wang; Xinchun Wang; Ming Hu; Lijun Zhu; Zhongqiu Liu
Journal:  Pharm Res       Date:  2017-04-18       Impact factor: 4.200

4.  Evaluation of 3,3',4'-trihydroxyflavone and 3,6,4'-trihydroxyflavone (4'-O-glucuronidation) as the in vitro functional markers for hepatic UGT1A1.

Authors:  Baojian Wu; Shuxing Zhang; Ming Hu
Journal:  Mol Pharm       Date:  2011-10-21       Impact factor: 4.939

5.  A novel local recycling mechanism that enhances enteric bioavailability of flavonoids and prolongs their residence time in the gut.

Authors:  Bijun Xia; Qiong Zhou; Zhijie Zheng; Ling Ye; Ming Hu; Zhongqiu Liu
Journal:  Mol Pharm       Date:  2012-10-24       Impact factor: 4.939

6.  Altered Expression of Small Intestinal Drug Transporters and Hepatic Metabolic Enzymes in a Mouse Model of Familial Alzheimer's Disease.

Authors:  Yijun Pan; Kotaro Omori; Izna Ali; Masanori Tachikawa; Tetsuya Terasaki; Kim L R Brouwer; Joseph A Nicolazzo
Journal:  Mol Pharm       Date:  2018-08-22       Impact factor: 4.939

7.  Intestinal absorption mechanisms of prenylated flavonoids present in the heat-processed Epimedium koreanum Nakai (Yin Yanghuo).

Authors:  Yan Chen; Yan Hong Zhao; Xiao Bin Jia; Ming Hu
Journal:  Pharm Res       Date:  2008-05-06       Impact factor: 4.200

8.  Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks.

Authors:  Olanrewaju Okusanya; Alan Forrest; Robin DiFrancesco; Sanela Bilic; Susan Rosenkranz; Michael F Para; Elizabeth Adams; Kevin E Yarasheski; Richard C Reichman; Gene D Morse
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

9.  In vivo pharmacokinetics of hesperidin are affected by treatment with glucosidase-like BglA protein isolated from yeasts.

Authors:  Yong-Mei Li; Xiao-Mian Li; Guang-Ming Li; Wen-Cai Du; Jing Zhang; Wei-Xia Li; Jianshe Xu; Ming Hu; Ze Zhu
Journal:  J Agric Food Chem       Date:  2008-06-21       Impact factor: 5.279

10.  Disposition of flavonoids via enteric recycling: UDP-glucuronosyltransferase (UGT) 1As deficiency in Gunn rats is compensated by increases in UGT2Bs activities.

Authors:  Stephen W J Wang; Kaustubh H Kulkarni; Lan Tang; Jing Rong Wang; Taijun Yin; Tomo Daidoji; Hiroshi Yokota; Ming Hu
Journal:  J Pharmacol Exp Ther       Date:  2009-03-05       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.